Bengaluru-based Indian biotech start-up Immuneel Therapeutics recently announced that it has started a Chimeric Antigen Receptor T cell therapy (CAR-T) trial named ‘IMAGINE’.

This Phase II trial is India’s first industry-sponsored CAR-T trial. The trial is being conducted in Narayana Hrudayalaya, Bengaluru, and patients are being enrolled.

Founded jointly by Biocon founder and chairperson Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, eminent US oncologist, and Dr. Kush Parmar, Immuneel, in 2019, aims to bring cell and gene therapy to India at an affordable cost.

Moneycontrol interacted with Dr. Arun Anand, Director and Chief Operating Officer, Immuneel Therapeutics, on the biotech start-up’s vision for cell therapy treatment, and other cellular immunotherapies for the management and treatment of cancers in India.

News Source: moneycontrol